WeekScoop

Two Faces of the Same Hormone

Oestrogen is simultaneously the hormone most associated with female vitality and the hormone most implicated in female cancer risk. The paradox resolves when you understand that oestrogen operates in a tissue-specific and context-dependent manner — its effects in premenopausal women are fundamentally different from its effects in postmenopausal women on hormone replacement therapy (HRT), and the difference is primarily determined by progesterone exposure and the metabolic context in which oestrogen acts.

The Premenopausal Protective Effect

In premenopausal women with normal ovulatory cycles, oestrogen exerts protective effects on the cardiovascular system — it upregulates HDL cholesterol, downregulates LDL cholesterol, maintains endothelial function, and supports the anti-inflammatory effects of nitric oxide. The cardiovascular protective effect of endogenous oestrogen explains the relatively low cardiovascular disease rates in premenopausal women compared to age-matched men. This protection is not present in anovulatory PCOS women, whose oestrogen exposure is lower and whose metabolic context is different, which is why PCOS is associated with elevated cardiovascular risk despite relatively higher oestrogen levels in some phases.

The bone-protective effect of oestrogen is well-established — oestrogen maintains osteoblast activity and suppresses osteoclast activity, keeping bone resorption in balance with bone formation. The sharp acceleration of bone loss after menopause, when oestrogen levels fall by 80-90%, establishes oestrogen as the primary determinant of female skeletal health across the lifespan. This is the clinical basis for the bone-protective effects of menopausal hormone therapy (MHT) when initiated within 10 years of menopause.

Why Postmenopausal Oestrogen Is Different

The postmenopausal oestrogen effect depends critically on whether oestrogen is administered with progesterone (combined MHT) or alone (oestrogen-only MHT). In women with an intact uterus, oestrogen-only MHT significantly increases endometrial cancer risk — the uterus is exposed to unopposed oestrogen without progesterone’s protective effect on the endometrium. In combined MHT, progesterone is administered concurrently, protecting the endometrium from oestrogen’s proliferative effects.

The breast cancer risk associated with combined MHT — a small but measurable increase in risk — is also modulated by the progesterone component. Oestrogen receptors are present in breast tissue, and oestrogen stimulates breast cell proliferation. Progesterone causes breast cell differentiation, which may reduce the mitogenic stimulus of oestrogen alone. The overall risk-benefit calculation for MHT depends on the individual patient’s risk profile: for women with no personal or family history of breast cancer, no significant cardiovascular risk, and bothersome menopausal symptoms, the quality-of-life benefit of MHT often outweighs the small absolute risk increase.

The Timing Hypothesis

The most important finding in the menopausal hormone therapy literature is the timing hypothesis — MHT initiated within 10 years of menopause and before age 60 has a favourable risk-benefit profile, including potential cardiovascular protection. MHT initiated more than 10 years after menopause is associated with elevated cardiovascular risk, because by then the cardiovascular protective effects of oestrogen are no longer operative and the pro-thrombotic effects of oestrogen dominate. This timing effect is one of the most important clinical considerations in the decision to initiate or continue MHT.

Bioidentical vs Synthetic Hormone Therapy

The distinction between bioidentical and synthetic hormone therapy is one of the most contested topics in menopausal medicine. Bioidentical hormones — 17-beta-oestradiol, progesterone, and testosterone — are structurally identical to the hormones produced by the human body. Synthetic hormones — medroxyprogesterone acetate (MPA), synthetic conjugated equine oestrogens — have different structures that produce different pharmacological effects in some tissues. The Women’s Health Initiative trial, which raised concerns about hormone therapy in the early 2000s, used synthetic conjugated oestrogens and MPA — a formulation that is not representative of the bioidentical hormones used in contemporary practice.

Contemporary evidence supports the use of transdermal 17-beta-oestradiol (patch or gel) plus micronised progesterone (oral) as the preferred menopausal hormone therapy formulation, with a risk-benefit profile that is substantially more favourable than the formulations used in the older WHI studies. The transdermal route bypasses first-pass hepatic metabolism, avoiding the thrombotic risk associated with oral oestrogen preparations. Micronised progesterone has a substantially better safety profile than MPA for breast cancer and cardiovascular outcomes.

What You Can Do Today

If you are considering menopausal hormone therapy, seek a practitioner who uses bioidentical hormones and can individualise the formulation and delivery route to your specific risk profile. Transdermal oestradiol patches or gels combined with oral micronised progesterone represent the current standard of care in integrative menopause management. Initiating therapy within 10 years of menopause onset — the window before age 60 — maximises the cardiovascular and bone-protective benefits while minimising risks. Annual monitoring of lipids, fasting glucose, and breast screening should accompany any MHT regimen.

Ready to support your health? Browse supplements on Gumroad — buy now from £8.

Oestrogen and the Brain

Oestrogen receptors are present throughout the brain — in the hippocampus (memory), prefrontal cortex (executive function), and brainstem (mood and sleep regulation). The loss of oestrogen after menopause produces measurable changes in brain structure: hippocampal volume decreases by 2-3% in the first 2 years after menopause, partially reversible with hormone therapy. The timing hypothesis applies to cognitive outcomes as clearly as cardiovascular outcomes: MHT initiated within 10 years of menopause shows protection against cognitive decline and dementia; MHT initiated after age 60 may be associated with worse cognitive outcomes. The window of opportunity is the same for both.

Testosterone in Women

Testosterone is essential for libido, energy, muscle mass, and cognitive function in women. Testosterone levels decline with age and after bilateral oophorectomy. The clinical use requires careful monitoring — testosterone is aromatised to oestrogen in adipose tissue, and excessive testosterone can produce virilisation. For women with documented low testosterone and symptoms of androgen deficiency, transdermal testosterone at doses that achieve physiological premenopausal levels is recommended, with monitoring to maintain levels in the mid-to-upper range of premenopausal women.